TABLE OF CONTENTS | |  | | Volume 37, Issue 43 |  | In this issue Article Correction Also new AOP
| |  |  |  | Article | | | Identification of highly penetrant Rb-related synthetic lethal interactions in triple negative breast cancer Rachel Brough, Aditi Gulati, Syed Haider, Rahul Kumar, James Campbell et al. Oncogene 2018 37 :5701 - 5718; June 18, 2018; 10.1038/s41388-018-0368-z Abstract | Full Text |  |  |  |  | The dimer-dependent catalytic activity of RAF family kinases is revealed through characterizing their oncogenic mutants Jimin Yuan, Wan Hwa Ng, Paula Y. P. Lam, Yu Wang, Hongping Xia et al. Oncogene 2018 37 :5719 - 5734; June 21, 2018; 10.1038/s41388-018-0365-2 Abstract | Full Text |  |  |  |  | PHLPP2 stabilization by p27 mediates its inhibition of bladder cancer invasion by promoting autophagic degradation of MMP2 protein Minggang Peng, Jingjing Wang, Dongyun Zhang, Honglei Jin, Jingxia Li et al. Oncogene 2018 37 :5735 - 5748; June 21, 2018; 10.1038/s41388-018-0374-1 Abstract | Full Text |  |  |  |  | MacroH2A1.2 inhibits prostate cancer-induced osteoclastogenesis through cooperation with HP1α and H1.2 Jin-Man Kim, Yonghwan Shin, Sunyoung Lee, Mi Yeong Kim, Vasu Punj et al. Oncogene 2018 37 :5749 - 5765; June 20, 2018; 10.1038/s41388-018-0356-3 Abstract | Full Text |  |  |  |  | The homeostasis-maintaining metabolites from bacterial stress response to bacteriophage infection suppress tumor metastasis Tianliang He, Min Jin, Chenxi Xu, Zhongjun Ma, Fufang Wu et al. Oncogene 2018 37 :5766 - 5779; June 20, 2018; 10.1038/s41388-018-0376-z Abstract | Full Text |  |  |  |  | C1GALT1 predicts poor prognosis and is a potential therapeutic target in head and neck cancer Mei-Chun Lin, Pin-Hui Chien, Hsin-Yi Wu, Syue-Ting Chen, Hsueh-Fen Juan et al. Oncogene 2018 37 :5780 - 5793; June 21, 2018; 10.1038/s41388-018-0375-0 Abstract | Full Text |  |  |  |  | FBXL14 abolishes breast cancer progression by targeting CDCP1 for proteasomal degradation Yan-Hong Cui, Hyeonmi Kim, Minyoung Lee, Joo Mi Yi, Rae-Kwon Kim et al. Oncogene 2018 37 :5794 - 5809; July 04, 2018; 10.1038/s41388-018-0372-3 Abstract | Full Text |  | Correction | | | Correction: Wild-type and mutated IDH1/2 enzymes and therapy responses Remco J. Molenaar, Jaroslaw P. Maciejewski, Johanna W. Wilmink & Cornelis J. F. van Noorden Oncogene 2018 37 :5810 - 5810; August 23, 2018; 10.1038/s41388-018-0455-1 Abstract | Full Text |  |  |  |  |  |  |  | Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here.
Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com |  |  |  |  |  | |  | Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Oncogene. In order to do so, please purchase a subscription. Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Oncogene. In order to do so, please purchase a subscription. This email has been sent to edgeblog.alerts.2011.001@gmail.com. If you no longer wish to receive the email alerts from Oncogene click here to unsubscribe . If you wish to discontinue all email services from Nature Research please click here to unsubscribe . For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Macmillan Publishers Limited is a company incorporated in England & Wales under company number 785998 & whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. Nature Research | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Nature is part of Springer Nature. © 2018 Springer Nature Limited. All rights reserved. |  | | |
No comments:
Post a Comment